EGFR and head and neck cancer: Others demonstrated that [89Zr]Zr-cetuximab tumor uptake in patients with advanced head and neck cancer did not correlate with EGFR expression in the tumor as a continuous variable, but SUV and tumor to background ratio were significantly higher in patients with a high versus low EGFR score [26].